Drug intelligence / Profile preview

exenatide + glucagon

Development stage
Unknown
Lead developer
Adocia
Modality
Peptides, Recombinant Proteins and Enzymes
Administration
Subcutaneous, Intramuscular, Intravenous, Intranasal
01

Overview

Exenatide + glucagon refers to a combination of two peptide hormones with distinct but potentially complementary mechanisms. Exenatide is a synthetic analog of glucagon-like peptide-1 (GLP-1) and acts as a GLP-1 receptor agonist, increasing glucose-dependent insulin secretion, suppressing inappropriate glucagon secretion, delaying gastric emptying, and reducing food intake. It is primarily used for the management of type 2 diabetes mellitus[1][2][5]. Glucagon itself is a hormone that raises blood glucose levels by stimulating hepatic glucose production; it is typically used in the treatment of severe hypoglycemia. While both agents are individually approved drugs, there is no evidence from the provided sources or current clinical practice guidelines that an exenatide + glucagon fixed-dose combination product exists or has been developed for any indication.

02

Targets

Beyond the preview

Go deeper on exenatide + glucagon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on exenatide + glucagon.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call